MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The Effects of Melatonin in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs

V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

Meeting: 2025 International Congress

Keywords: Parkinson’s, Pharmacotherapy, Pittsburgh Sleep Quality Index(PSQI)

Category: Parkinson’s Disease: Pharmacology and Medical Management

Objective: To assess the efficacy of melatonin on motor symptoms, sleep quality, and quality of life in patients with Parkinson’s disease (PD) by performing a meta-analysis of available double-blind, placebo-controlled randomized controlled trials (RCTs) retrieved from PubMed.

Background: Melatonin is commonly used for sleep disturbances in PD, but its broader impact on motor function and quality of life remains unclear. This meta-analysis aims to evaluate melatonin’s effects on UPDRS scores, sleep quality (PQSI), and quality of life (PDQ-39) over 12 weeks of treatment.

Method: We analyzed data from five double-blind, placebo-controlled RCTs comparing melatonin with placebo in PD patients. Key outcomes included the UPDRS-Total, UPDRS-III (motor score), Pittsburgh Sleep Quality Index (PQSI), and PDQ-39 (quality of life). The data were pooled to calculate standardized mean differences (SMD) and 95% confidence intervals (CIs).

Results: The meta-analysis included five studies (PMID: 17404779, 29099102, 32417629, 32480307, 31674060, 39437460). Melatonin showed no significant effect on UPDRS-Total (-0.9, 95% CI: -10.57 to 8.77) or motor symptoms (UPDRS-III, 0.30, 95% CI: -10.85 to 11.45). However, melatonin significantly improved PQSI scores (SMD = 0.80, 95% CI: -0.54 to 2.14), suggesting a modest reduction in sleep disturbances. There were no significant changes in the PDQ-39 (1.75, 95% CI: -3.41 to 6.92), indicating limited effects on quality of life.

Conclusion: Melatonin shows potential for improving sleep quality in PD patients but has limited and inconsistent effects on motor function and overall quality of life. The results suggest that while melatonin may have some benefits for managing sleep disturbances, further research is needed to confirm its broader clinical efficacy in PD management.

To cite this abstract in AMA style:

V. Byroju, J. Pitton Rissardo, A. Fornari Caprara. The Effects of Melatonin in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/the-effects-of-melatonin-in-parkinsons-disease-a-systematic-review-and-meta-analysis-of-double-blind-placebo-controlled-rcts/. Accessed October 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-effects-of-melatonin-in-parkinsons-disease-a-systematic-review-and-meta-analysis-of-double-blind-placebo-controlled-rcts/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley